Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Jul 26;7:6629. doi: 10.1038/s41598-017-06643-9

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2017

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Inhibition of STAT3 reduced MDSC and TAM population in mice with ASCC. (a) MDSC population was monitored by CD11b⁺Gr-1⁺flow cytometry in peripheral blood and spleen. S3I-201 treatment notably reduced the proportion of MDSCs in total lymphocytes. (b) Quantification of the results. (c) Representative immunofluorescent staining of CD11b⁺Gr-1⁺ in mice ASCC. Visible reduction of MDSCs populations in the S3I-201 treatment group was seen. (d) TAM population was monitored by CD11b⁺F4/80⁺ flow cytometry in peripheral blood and spleen. S3I-201 treatment notably reduced the proportion of TAMs in total lymphocytes. (e) Quantification of the results. (f) CD11b⁺Gr-1⁺ and CD11b⁺F4/80⁺ populations in the tumor bed were significantly reduced after S3I-201 treatment. **P < 0.01; ***P < 0.001.